Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PFSCF ProMetic Life Sciences	$5.47	$5.47	$5.47 ▼ $352.00	$127.45M	2.46	279 shs	N/A
SIGA Siga Technologies	$6.61 -1.3%	$6.31	$4.95 ▼ $12.83	$472.22M	0.94	712,416 shs	271,604 shs
TRUU True Drinks	$0.10 +2.8%	$0.10	$0.00 ▼ $0.08	$483.05M	10.9	1.01 million shs	1,510 shs
VALN Valneva	$6.43 -1.1%	$6.10	$3.62 ▼ $8.66	$547.13M	1.74	42,745 shs	2,566 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PFSCF ProMetic Life Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
SIGA Siga Technologies	-1.18%	-2.90%	+6.35%	+11.85%	-25.64%
TRUU True Drinks	+2.79%	+0.94%	-9.21%	-2.86%	-44.97%
VALN Valneva	-0.54%	+7.14%	+9.78%	-4.93%	-16.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	2.0352 of 5 stars	0.0	3.0	0.0	0.0	1.5	0.8	3.1
TRUU True Drinks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VALN Valneva	1.8243 of 5 stars	3.5	3.0	0.0	0.0	1.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PFSCF ProMetic Life Sciences	0.00	N/A	N/A	N/A
SIGA Siga Technologies	0.00	N/A	N/A	N/A
TRUU True Drinks	0.00	N/A	N/A	N/A
VALN Valneva	3.00	Buy	$15.50	139.57% Upside

Current Analyst Ratings Breakdown

Latest PFSCF, VALN, TRUU, and SIGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/8/2025	VALN Valneva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PFSCF ProMetic Life Sciences	$36.55M	3.49	N/A	N/A	($67.63) per share	-0.08
SIGA Siga Technologies	$138.72M	3.42	$0.82 per share	8.10	$3.02 per share	2.20
TRUU True Drinks	$1.95M	247.72	N/A	N/A	($0.03) per share	-3.24
VALN Valneva	$183.52M	3.00	$0.10 per share	66.42	$2.41 per share	2.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PFSCF ProMetic Life Sciences	-$150.73M	N/A	0.00	∞	N/A	-894.02%	-3,350.55%	-67.76%	N/A
SIGA Siga Technologies	$59.21M	$0.67	9.93	5.31	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)
TRUU True Drinks	-$3.88M	$0.01	9.71	∞	N/A	-255.80%	N/A	-165.86%	N/A
VALN Valneva	-$13.25M	-$1.19	N/A	N/A	N/A	-43.08%	-43.05%	-16.23%	8/12/2025 (Estimated)

Latest PFSCF, VALN, TRUU, and SIGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	VALN Valneva	-$0.27	N/A	N/A	N/A	$46.28 million	N/A
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/7/2025	Q1 2025	VALN Valneva	-$0.40	-$0.13	+$0.27	-$0.13	$41.80 million	$51.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
TRUU True Drinks	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PFSCF ProMetic Life Sciences	N/A	0.95	0.71
SIGA Siga Technologies	N/A	8.40	6.28
TRUU True Drinks	N/A	0.01	N/A
VALN Valneva	0.92	2.70	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PFSCF ProMetic Life Sciences	0.10%
SIGA Siga Technologies	55.40%
TRUU True Drinks	N/A
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
PFSCF ProMetic Life Sciences	N/A
SIGA Siga Technologies	1.95%
TRUU True Drinks	18.18%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PFSCF ProMetic Life Sciences	50	23.31 million	N/A	Not Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable
TRUU True Drinks	40	4.97 billion	N/A	Not Optionable
VALN Valneva	700	85.09 million	72.41 million	Not Optionable

PFSCF, VALN, TRUU, and SIGA Headlines

Recent News About These Companies

Valneva (NASDAQ:VALN) Shares Gap Up - Here's What Happened

July 15 at 1:18 PM | marketbeat.com

Valneva's chikungunya vaccine suspension gets lifted for older adults

July 11, 2025 | msn.com

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

July 11, 2025 | globenewswire.com

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

July 11, 2025 | reuters.com

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

June 26, 2025 | globenewswire.com

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

June 25, 2025 | globenewswire.com

Valneva Scotland earns prestigious global health and safety award

June 24, 2025 | msn.com

Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure

June 10, 2025 | indiaeducationdiary.inI

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

June 10, 2025 | reuters.com

Valneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in Children

June 10, 2025 | pharmexec.comP

UK restricts use of Valneva chikungunya vaccine for safety review

June 10, 2025 | yahoo.com

UK's MHRA suspends Valneva's chikungunya vaccine for elderly (June 9)

June 10, 2025 | msn.com

Valneva reports data from Phase II chikungunya vaccine trial in children

June 6, 2025 | finance.yahoo.com

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

June 5, 2025 | globenewswire.com

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

June 4, 2025 | globenewswire.com

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025 | globenewswire.com

US CDC accepts recommendations for chikungunya vaccines

May 21, 2025 | msn.com

London man among thousands who've rolled up their sleeves to trial Lyme disease vaccine

May 19, 2025 | cbc.ca

US Advises Older Travelers to Avoid Chikungunya Vaccine

May 16, 2025 | infectiousdiseaseadvisor.comI

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

May 15, 2025 | pharmexec.comP

FDA, CDC recommend pause in Valneva chikungunya vaccine for older adults

May 13, 2025 | cidrap.umn.eduC

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSCF, VALN, TRUU, and SIGA Company Descriptions

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)

As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Siga Technologies NASDAQ:SIGA

$6.61 -0.09 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$6.61 0.00 (0.00%)

As of 04:39 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

True Drinks OTCMKTS:TRUU

$0.10 +0.00 (+2.75%)

As of 07/16/2025

True Drinks Holdings, Inc. markets and distributes nutritional supplement drinks. The company sells Bazi All Natural Energy, a liquid nutritional supplement drink through drinkbazi.com. It also formulates products containing CBD; and produces and distributes vapor products in approximately 90 countries. The company was formerly known as True Drinks, Inc. and changed its name to True Drinks Holdings, Inc. in October 2012. True Drinks Holdings, Inc. was founded in 2008 and is headquartered in Irvine, California.

Valneva NASDAQ:VALN

$6.43 -0.07 (-1.08%)

As of 04:00 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time